Recent 8-K filings for RDGL
Highest-materiality recent filing
Vivos reports positive initial RadioGel clinical trial results; plans expansion to 50 patients
- First 5 patients showed safety; Y-90 remained at injection site with no adverse events.
- One patient (cancerous node near trachea) showed over 80% reduction in tumor size and metastatic activity.
-
Vivos director Cadwell buys 250K Series D preferred for $250K; Series C canceled
Director Carl Cadwell agreed to purchase 250,000 shares of Series D Convertible Preferred at $1.00/share, a $250,000 purchase price paid by wire transfer on October 1, 2026.
-
Certificate of Designations filed with Delaware on Sept 28, 2026 designates 1.0M of the company's 10.0M authorized preferred shares as Series D Convertible Preferred, par value $0.001.
-
Vivos appoints Brad Allan Weeks as President and David J. Swanberg as COO, effective Sept 1, 2025
Weeks appointed President; base salary $192,000/yr plus $3,000/month in common stock.
-
Vivos appoints Brad Allan Weeks as President and David J. Swanberg as COO
Brad Allan Weeks appointed President effective Sept 1, 2025, with base salary $192,000/yr plus monthly stock grants.
-
Vivos Inc. creates wholly owned India subsidiary for manufacturing and therapies
Board approved creation of Vivos Scientific India LLP on September 17, 2025.
-
Vivos raises $1.5M via 12.5M share sale; also issues warrants for 6.25M shares at $0.15
Issued 12.5M common shares to an accredited investor for gross proceeds of $1.5M under Regulation A+ offering.
-
Vivos reports positive initial RadioGel clinical trial results; plans expansion to 50 patients
First 5 patients showed safety; Y-90 remained at injection site with no adverse events.
-
Vivos files IDE amendment with FDA to initiate human trials of Radiogel therapy
Filed IDE amendment with FDA for Radiogel™ Precision Radionuclide Therapy, addressing 63 prior FDA comments.
-
Vivos Inc. renews CEO Michael Korenko's employment agreement with $295,500 salary, 20,000 RSUs
Dr. Michael Korenko continues as CEO under two-year term effective January 1, 2024.
-
Vivos raises $520k via 8.13M share sale; completes warrant exchanges and amendments
Gross proceeds of $520,448 from sale of 8,132,000 shares of common stock at ~$0.064 per share under Regulation A+.
-
Vivos posts quarterly update: patent progress, Y-90 cost cut, new clinics
Filed utility patent for chiller; hydrogel patent nationalized in over 10 offices covering 63 countries.
-
Vivos completes $640k Regulation A+ stock offering and issues warrants for up to 10.7M shares
Raised $640,000 in gross proceeds from sale of 8,000,000 shares.
-
Vivos raises $1.2M from 15M share sale and $20K from warrant issuance
Gross proceeds of $1.2M from 15M shares of common stock sold under Regulation A+ on July 7, 2022.
-
Vivos 2021 recap: first equine IsoPet therapy, FDA pre-sub for RadioGel IDE, production improved 3x
University of Missouri performed first equine IsoPet therapy; excellent outcome confirmed after monitoring.
Materiality & sentiment trend
Max materiality 0.65 · Median 0.50 · Most common event other_material